Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab.
10.3341/kjo.2010.24.3.179
- Author:
Na Rae KIM
1
;
Hee Seung CHIN
Author Information
1. Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea. hschin@inha.ac.kr
- Publication Type:Case Report ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Central retinal vein occlusion
- MeSH:
Antibodies, Monoclonal/*administration & dosage;
Disease Progression;
Female;
Fluorescein Angiography;
Glaucoma, Neovascular/complications;
Humans;
Injections, Intraocular;
Ischemia/diagnosis/*etiology/physiopathology;
Middle Aged;
Retinal Vein Occlusion/*complications/*drug therapy/physiopathology;
*Retinal Vessels;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity/drug effects;
Vitreous Body
- From:Korean Journal of Ophthalmology
2010;24(3):179-181
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.
